RecallRadar

FDA Drug recall D-0130-2025

Dabigatran Etexilate, 150mg capsules, 60-count bottles, Rx Only, Manufactured by: Alkem Laboratories Ltd., INDIA, Distributed by: Ascend La…

On 2024-12-18 the FDA classified a Class II recall of Dabigatran Etexilate, 150mg capsules, 60-count bottles, Rx Only, Manufactured by: Alkem Laboratories Ltd., INDIA, Distributed by: Ascend La… by Ascend Laboratories, citing CGMP Deviations: Presence of N-nitroso-Dabigatran impurity above recommended interim limit.

Read the official FDA Drug notice

AgencyFDA Drug
Recall numberD-0130-2025
ClassificationClass II
Statusongoing
Initiated2024-12-12
Published2024-12-18
Last updated2026-09-13 11:52 UTC
CompanyAscend Laboratories
DistributionUS

Product

Dabigatran Etexilate, 150mg capsules, 60-count bottles, Rx Only, Manufactured by: Alkem Laboratories Ltd., INDIA, Distributed by: Ascend Laboratories, LLC Parsippany, NJ 07054 NDC 67877-475-60

Reason

CGMP Deviations: Presence of N-nitroso-Dabigatran impurity above recommended interim limit

Identifiers

ndc67877-475-60
ndc67877-474-60
ndc67877-624-60
ndc67877-624-31
code_infoLot #: 24142192, 24142193, 24142194, Exp. Date April 30, 2026; 24142463, Exp. Date May 31, 2026;

Status history

No status changes recorded since RecallRadar first saw this recall on 2026-09-13 11:52 UTC. Current status: ongoing.

Source

Official record: https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0130-2025%22

RecallRadar indexes public recall notices from the FDA, USDA FSIS, and CPSC. The official agency notice is the authoritative source. Always confirm details at the linked source before acting.